Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Video interview with dr. Patrick Brown about post-reinduction therapy with blinatumomab in younger relapsed
B-cell ALL patients
2. Rivaroxaban for pediatric patients suffering a venous thromboembolism
3. Adding daratumumab to carfilzomib-dexamethasone significantly reduces the risk of disease progression in
patients with relapsed/refractory MM
4. Maintenance therapy with the hypomethylating agent CC-486 significantly prolongs the overall and relapse-
free survival of AML patients in remission after induction chemotherapy
5. Four-year follow-up data of ECHELON-1 support the robust and durable benefit of brentuximab vedotin + AVD
over ABVD as frontline treatment for advanced Hodgkin lymphoma